

February 07, 2020

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Friday, February 07, 2020

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Board of Directors of Zota Health Care Limited (the "Company") in its Meeting held on Friday, February 07, 2020 at 03:00 P.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat – 395002 have, *inter alia*, discussed and approved the following business:

1. Considered and approved unaudited standalone and consolidated financial results for the quarter and nine months ended on December 31, 2019 along with Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (*Annexure – I*).

Further, unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company is listed i.e. at www.nseindia.com and on Company's website at www.zotahealthcare.com

The Board meeting concluded at 05:50 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited



Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat



Encl: a/a

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors of

Zota Health Care Limited


1. We have reviewed the accompanying statement of unaudited financial results of **Zota Health Care Limited** (the "Company") for the quarter and nine months ended **December 31, 2019** (the "Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Attention is drawn to Note no.3 of the Statement which states that the Comparative figures of quarter and nine months ended December 31, 2018 as reported in the accompanying Statement have been restated by the management of the Company and prepared by exercising necessary due diligence to ensure that the financial results reflect true and fair view of Company's affairs but have not been subjected to review.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 07/02/2020

Place: Surat



For Shivangi Parekh & Co.
Chartered Accountants

ICAI FRN: 131449W

CA. Shivangi Mehta

Proprietor

M. No. 118936

UDIN: 20118936AAAAI5167

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,
SURAT-395002.

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

**The Board of Directors of
Zota Health Care Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and nine months ended December 31, 2019** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (the "Regulation").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Attention is drawn to Note no. 3 of the Statement which states that the Comparative figures of quarter and nine months ended December 31, 2018 as reported in the accompanying Statement have been restated by the management of the Company and prepared by exercising necessary due diligence to ensure that the financial results reflect true and fair view of Company's affairs but have not been subjected to review.

4. The Statement includes the results of the following entities:
 - a. Zota Health Care Limited (Parent)
 - b. Zota Healthcare Lanka (Pvt) Ltd (Subsidiary)

**302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,
SURAT-395002.**


SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

5. Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements of the subsidiary included in the consolidated unaudited financial results that reflect total revenues of Rs. Nil, total net loss after tax of Rs. 3148 and Rs. 8528 and total comprehensive loss of Rs.3148 and Rs. 8528, for the quarter and nine months ended 31.12.2019, respectively, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

Date: 07/02/2020
Place: Surat




For Shivangi Parekh & Co.
Chartered Accountants
ICAI FRN: 131449W

S. Mehta
CA. Shivangi Mehta
Proprietor
M. No.118936

UDIN: 20118936AAAAAJ2496


Particulars		Quarter Ended			Nine Months Ended		Year Ended
		31/12/2019 (Unaudited)	30/09/2019 (Unaudited)	31/12/2018 (Unaudited) (Refer Note-3&4)	31/12/2019 (Unaudited)	31/12/2018 (Unaudited) (Refer Note-3&4)	31/03/2019 (Audited)
I.	Revenue from Operations	2506.38	2528.75	2176.47	7203.31	6503.02	8562.94
II.	Other Incomes	30.74	37.49	17.38	98.04	117.63	154.47
III.	Total Revenue	2537.11	2566.24	2193.85	7301.35	6620.66	8717.42
IV.	Expenses:						
	Cost of Materials Consumed:	430.07	179.70	297.84	972.23	783.31	1151.00
	Purchases of Stock-in-Trade	1069.13	1451.28	1366.34	3567.99	4313.27	5276.35
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	287.15	163.86	-131.11	540.48	-733.98	-725.97
	Employee Benefit Expenses	263.00	258.99	228.39	765.50	631.14	889.19
	Finance Costs	2.31	1.02	1.45	4.63	2.16	3.68
	Depreciation / Amortisation and Depletion Expense	48.08	32.05	37.14	110.16	113.07	139.42
	Other Expenses	383.67	332.94	388.34	1056.47	898.30	1197.81
	Total Expenses	2483.41	2419.84	2188.39	7017.46	6007.29	7931.49
V.	Profit before Exceptional Items and tax from continuing operations (III-IV)	53.71	146.40	5.45	283.89	613.37	785.92
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(loss) before tax	53.71	146.40	5.45	283.89	613.37	785.92
VIII.	Tax Expense:						
	(1) Current tax	15.80	36.81	-18.68	73.69	179.29	232.43
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	0.13	0.26	2.34	2.34
	(2) Deferred Tax	0.14	-0.49	3.77	-6.62	8.47	4.03
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	38.04	109.11	27.78	203.33	440.21	555.19
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-	-
XIII.	Profit/ (Loss) for the Year	38.04	109.11	27.78	203.33	440.21	555.19
XIV.	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Statement of profit and loss	0.18	4.59	-	16.27	-	-9.22
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	-0.05	-1.15	-	-4.09	-	2.56
	B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
	Other comprehensive income for the year, net of tax	0.13	3.43	-	12.18	-	-6.65
	Total comprehensive income for the year (XIII + XIV)	38.18	112.54	27.78	215.50	440.21	548.54
	Paid-up Equity Share Capital	2456.03	2456.03	1754.34	2456.03	1754.34	1754.34
	Earnings per equity share of face value of ₹ 10 each						
	(1) Basic (in ₹)	0.15	0.44	0.11	0.83	1.79	2.26
	(2) Diluted (in ₹)	0.15	0.44	0.11	0.83	1.79	2.26

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Company Secretary
Ashvin Variya


Chief Financial Officer
Viral Mandviwala

Shivangi Parekh & Co.
Chartered Accountants


CA. Shivangi Mehta
Proprietor
M. No. 118936
Firm No. 131449W

Date: 07-02-2020
Place : Surat

Registered Office :


Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31/12/2019 (Unaudited)	30/09/2019 (Unaudited)	31/12/2018 (Unaudited) (Refer Note-3&4)	31/12/2019 (Unaudited)	31/12/2018 (Unaudited) (Refer Note-3&4)	31/03/2019 (Audited)
I. Revenue from Operations	2506.38	2528.75	2176.47	7203.31	6503.02	8562.94
II. Other Incomes	30.74	37.49	17.38	98.04	117.63	154.47
III. Total Revenue	2537.11	2566.24	2193.85	7301.35	6620.66	8717.42
IV. Expenses:						
Cost of Materials Consumed:	430.07	179.70	297.84	972.23	783.31	1151.00
Purchases of Stock-in-Trade	1069.13	1451.28	1366.34	3567.99	4313.27	5276.35
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	287.15	163.86	-131.11	540.48	-733.98	-725.97
Employee Benefit Expenses	263.00	258.99	228.39	765.50	631.14	889.19
Finance Costs	2.31	1.02	1.45	4.64	2.16	3.68
Depreciation / Amortisation and Depletion Expense	48.08	32.05	37.14	110.16	113.07	139.42
Other Expenses	383.71	332.98	388.70	1056.55	898.66	1198.16
Total Expenses	2483.44	2419.88	2188.75	7017.55	6007.64	7931.84
V. Profit before Exceptional items and tax from continuing operations (III-IV)	53.68	146.36	5.10	283.80	613.01	785.57
VI. Exceptional Items	-	-	-	-	-	-
VII. Profit/(loss) before tax	53.68	146.36	5.10	283.80	613.01	785.57
VIII. Tax Expense:						
(1) Current tax	15.80	36.81	-18.68	73.69	179.29	232.43
(1.1) I.T. & DD Tax Provision Created Short/ excess	0.00	0.00	0.13	0.26	2.34	2.34
(2) Deferred Tax	0.14	-0.49	3.77	-6.62	8.47	4.03
IX. Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	38.01	109.07	27.42	203.24	439.85	554.84
X. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI. Tax Expense of discontinued Operations	-	-	-	-	-	-
XII. Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-	-
XIII. Profit/ (Loss) for the Year	38.01	109.07	27.42	203.24	439.85	554.84
XIV. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	0.18	4.59	0.00	16.27	0.00	-9.22
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	-0.05	-1.15	0.00	-4.09	0.00	2.56
B (i) Items that will be reclassified to Statement of profit and loss	0.01	-0.09	-0.11	-0.08	-0.11	0.01
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	0.00
Other comprehensive income for the year, net of tax	0.15	3.34	-0.11	12.10	-0.11	-6.64
Total comprehensive income for the year (XIII + XIV)	38.16	112.41	27.31	215.34	439.75	548.20
Profit attributable to:						
Owners of the parent	38.01	109.07	27.42	203.24	439.85	554.84
Non-controlling interest	-	-	-	-	-	-
Other comprehensive income attributable to:						
Owners of the parent	0.15	3.34	-0.11	12.10	-0.11	-6.64
Non-controlling interest	-	-	-	-	-	-
Paid-up Equity Share Capital	2456.03	2456.03	1754.34	2456.03	1754.34	1754.34
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	0.15	0.44	0.11	0.83	1.79	2.26
(2) Diluted (in ₹)	0.15	0.44	0.11	0.83	1.79	2.26

For and on behalf of the Board



(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)



(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Company Secretary
Ashvin Variya
Date: 07/02/2020
Place : Surat


Chief Financial Officer
Viral Mandviwala


Shivangi Parekh & Co.
Chartered Accountants


CA. Shivangi Mehta
Proprietor
M. No. 118936
Firm No. 131449W


Registered Office :


Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Notes:

1. The above financial results for the quarter and nine months ended December 31, 2019 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 07, 2020.
2. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine months ended December 31, 2019.
3. The Company has migrated to the main Board of National Stock Exchange w.e.f. August 19, 2019 accordingly the Company has not prepared financial results for the quarter and nine months ended December 31, 2018. However, Comparative figures of quarter and nine months ended December 31, 2018 have been restated by the management of the Company and prepared by exercising necessary due diligence to ensure that the financial results reflect true and fair view of Company's affairs. Financial results for the quarter and nine months ended December 31, 2018 have not been subjected to limited review report of auditor.
4. Till 31st March, 2019, the company has obtained Actuarial Valuation Report of Gratuity on half yearly basis; hence the respective figures of actuarial gain or loss have not been considered for the quarter and nine months ended December 31, 2018. However, this does not have any material impact on the results of the said period.
5. The Company has evaluated its Operating segment in accordance with IND AS 108 and has concluded that it is engaged in a single operating segment.
6. The consolidated results include the result of Company's wholly owned subsidiary company Zota Healthcare Lanka (Pvt) Ltd.
7. Tax expenses for the quarter and nine months ended December 31, 2019 have been calculated as per Taxation Laws (Amendment) Ordinance 2019, the income-tax is calculated at the reduced rate from the current financial year.
8. On July 29, 2019 Company has issued 7016975 bonus shares in the ratio of 4:10 [i.e. 4 (Four) fully paid up equity shares for every 10 (Ten) equity shares held.] Earning Per Share (EPS) for all the reporting period before the said bonus issue have been restated as per IND AS 33.
9. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

**Registered Office :**

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122